Angela Hückelhoven

Title: Angela Hückelhoven: Innovator in Influenza Research

Introduction

Angela Hückelhoven is a prominent inventor based in Berglen, Germany. She has made significant contributions to the field of immunology, particularly in the detection, prevention, and treatment of influenza. Her innovative work has led to the development of a unique T-cell receptor that targets influenza viruses.

Latest Patents

Angela Hückelhoven holds a patent for an "Influenza-specific T-cell receptor and its uses in the detection, prevention and/or treatment of influenza." This invention relates to specific T-cell receptor alpha-chains, beta-chains, and T-cell receptors that bind to the influenza matrix peptide GILGFVFTL (GL9 peptide) presented by Human Leukocyte antigen A2 (HLA-A2) molecules. The patent also covers soluble TCR constructs, chimeric TCRs, nucleic acids, expression constructs, and cells that incorporate these TCR chains. Furthermore, it discusses the use of these TCRs as a medicament for influenza detection, prevention, and treatment.

Career Highlights

Angela is affiliated with Friedrich-Alexander-Universität Erlangen-Nürnberg, where she conducts her research. Her work has been instrumental in advancing the understanding of T-cell responses to influenza, paving the way for new therapeutic strategies.

Collaborations

Angela collaborates with Thomas Harrer, contributing to the innovative research environment at her institution. Their combined expertise enhances the potential for breakthroughs in influenza treatment.

Conclusion

Angela Hückelhoven's contributions to influenza research exemplify the impact of innovative thinking in the medical field. Her patent and ongoing research efforts are vital in the fight against influenza, showcasing the importance of scientific advancements in public health.